Issue 6/2012

  • Obama’s new biobased economy

    In this issue:

    • Cover Story: Obama’s new biobased economy - The bioeconomy begins to go truly global
    • GSK absorbs Cellzome; German biotech sector expanding
    • Abbott buys kidney treatment from Action Pharma
    • DSM enters biomedicine with takeover of Kensey Nash
    • SPECIAL: BiobasedWorld at Achema – The guide to the trade fair
    • Zeltia pockets Yondelis milestone from Johnson & Johnson
    • Selvita stuffs its war-chest with shares, grants and awards
    • Pattern of DNA methylation determines genome stability

Volume 2016

Volume 2015

Volume 2014

Volume 2013

Volume 2012

© 2007-2016 BIOCOM

http://www.european-biotechnology-news.com/magazine/ebsin/2012/6/pos/1.html?sort=asc&cHash=bfd90e2d54056358af1b4a091bcb4f71

Kurszettel

Alle Kurse

TOP

  • BIOTIE THERAPEUTICS (FI)0.27 EUR92.86%
  • PLETHORA (UK)3.38 GBP12.67%
  • ZEALAND PHARMA (DK)130.50 DKK11.06%

FLOP

  • BIOFRONTERA (D)2.84 EUR-4.70%
  • CHRONTECH PHARMA (S)0.34 SEK-2.86%
  • PHOTOCURE (N)41.50 NOK-2.35%

TOP

  • THERAMETRICS (CH)0.03 CHF50.0%
  • GALAPAGOS (B)52.23 EUR30.5%
  • NICOX (F)10.89 EUR26.3%

FLOP

  • MOBERG PHARMA (S)38.70 SEK-21.8%
  • BIONOR PHARMA (N)0.70 NOK-21.3%
  • BIOCARTIS GROUP NV (B)8.32 EUR-18.4%

TOP

  • CHRONTECH PHARMA (S)0.34 SEK3300.0%
  • KARO BIO (S)29.50 SEK1853.6%
  • NICOX (F)10.89 EUR485.5%

FLOP

  • NEUROVIVE PHARMACEUTICAL AB (S)5.95 SEK-87.8%
  • BB BIOTECH (D)44.62 EUR-84.6%
  • BIOTEST (D)17.10 EUR-77.8%

No liability assumed, Date: 26.05.2016